Saturday, March 18, 2017

PCSK9 Antidrug Antibodies: Not a Class Effect

(MedPage Today) -- Alirocumab clear of problems seen with bococizumab, researchers say
via PCSK9 Antidrug Antibodies: Not a Class Effect
by
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)